Greenblatt, David J.

A method for estimating the probability of adverse drug reactions

Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics

Pharmacovigilance and Adverse Drug ReactionsReliability and Agreement in Measurement

Cited by 11,914

Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance

Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics

Pharmacogenetics and Drug MetabolismAntifungal resistance and susceptibility

Cited by 508

Use of benzodiazepines in anxiety disorders

Wood, A. J. J., Shader, R. I., & Greenblatt, D. J. (1993) · New England Journal of Medicine

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesSynthesis and pharmacology of benzodiazepine derivatives

Cited by 341

Sensitivity to triazolam in the elderly

Greenblatt, D. J., Harmatz, J. S., Shapiro, L., Engelhardt, N., Gouthro, T. A., & Shader, R. I. (1991) · New England Journal of Medicine

Pharmaceutical Practices and Patient OutcomesAnesthesia and Sedative Agents

Cited by 258

Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans

Greenblatt, D. J., Shader, R. I., Franke, K., MacLaughlin, D. S., Harmatz, J. S., Allen, M. D., Werner, A., & Woo, E. (1979) · Journal of Pharmaceutical Sciences

Pharmacogenetics and Drug MetabolismAnesthesia and Sedative Agents

Cited by 197

Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam

Greenblatt, D. J., Divoll, M., Harmatz, J. S., & Shader, R. I. (1982) · Journal of Pharmaceutical Sciences

Pharmacogenetics and Drug MetabolismAnesthesia and Sedative Agents

Cited by 134

Imipramine and Buspirone in Treatment of Patients With Generalized Anxiety Disorder Who Are Discontinuing Long-Term Benzodiazepine Therapy

Rickels, K., DeMartinis, N., García-España, F., Greenblatt, D. J., Mandos, L. A., & Rynn, M. (2000) · American Journal of Psychiatry

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesSubstance Abuse Treatment and Outcomes

Cited by 110

Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration

Greenblatt, D. J., Harmatz, J. S., Singh, N. N., Steinberg, F., Roth, T., Moline, M. L., Harris, S. C., & Kapil, R. P. (2014) · The Journal of Clinical Pharmacology

Pharmacogenetics and Drug MetabolismAnesthesia and Sedative Agents

Cited by 107

Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men

Olubodun, J. O., Ochs, H. R., Von Moltke, L. L., Roubenoff, R., Hesse, L. M., Harmatz, J. S., Shader, R. I., & Greenblatt, D. J. (2003) · British Journal of Clinical Pharmacology

Pharmacogenetics and Drug MetabolismPharmaceutical studies and practices

Cited by 104

Implications of Altered Drug Disposition in the Elderly: Studies of Benzodiazepines

Greenblatt, D. J., Shader, R. I., & Harmatz, J. S. (1989) · The Journal of Clinical Pharmacology

Pharmaceutical Practices and Patient OutcomesPharmacogenetics and Drug Metabolism

Cited by 102

Comparative Hypnotic Effects of Flurazepam, Triazolam, and Placebo: A Long-Term Simultaneous Nighttime and Daytime Study

MITLER, M. M., SEIDEL, W. F., DEN HOED, J. V., GREENBLATT, D. J., & DEMENT, W. C. (1984) · Journal of Clinical Psychopharmacology

Sleep and related disordersPain Management and Placebo Effect

Cited by 98

Effect of Gradual Withdrawal on the Rebound Sleep Disorder after Discontinuation of Triazolam

Greenblatt, D. J., Harmatz, J. S., Zinny, M. A., & Shader, R. I. (1987) · New England Journal of Medicine

Sleep and related disordersSubstance Abuse Treatment and Outcomes

Cited by 96

Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate

GREENBLATT, D., HARMATZ, J., VONMOLTKE, L., WRIGHT, C., & SHADER, R. (2004) · Clinical Pharmacology & Therapeutics

Pharmacogenetics and Drug MetabolismPharmaceutical studies and practices

Cited by 93

Benzodiazepine Sensitivity in Panic Disorder: Effects of Chronic Alprazolam Treatment

Cowley, D. S., Roy-Byrne, P. P., Radant, A., Ritchie, J. C., Greenblatt, D. J., Nemeroff, C. B., & Hommer, D. W. (1995) · Neuropsychopharmacology

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesNeuroscience and Neuropharmacology Research

Cited by 87

From Disordered Eating to Addiction: The “Food Drug” in Bulimia Nervosa

Umberg, E. N., Shader, R. I., Hsu, L. K. G., & Greenblatt, D. J. (2012) · Journal of Clinical Psychopharmacology

Eating Disorders and BehaviorsNutrition, Health and Food Behavior

Cited by 52

Clorazepate and lorazepam: clinical improvement and rebound anxiety

Rickels, K., Fox, I., Greenblatt, D. J., Sandler, K. R., & Schless, A. P. (1988) · American Journal of Psychiatry

Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesTreatment of Major Depression

Cited by 50

Benzodiazepine receptor binding of nonbenzodiazepines in vivo: alpidem, zolpidem and zopiclone

Byrnes, J. J., Greenblatt, D. J., & Miller, L. G. (1992) · Brain Research Bulletin

Neuroscience and Neuropharmacology ResearchNicotinic Acetylcholine Receptors Study

Cited by 46

Desmethyldiazepam pharmacokinetics: studies following intravenous and oral desmethyldiazepam, oral clorazepate, and intravenous diazepam

Greenblatt, D. J., Divoll, M. K., Soong, M. H., Boxenbaum, H. G., Harmatz, J. S., & Shader, R. I. (1988) · The Journal of Clinical Pharmacology

Pharmacogenetics and Drug MetabolismAnesthesia and Sedative Agents

Cited by 42

International Task Force on Benzodiazepines

Balon, R., Chouinard, G., Cosci, F., Dubovsky, S. L., Fava, G. A., Freire, R. C., Greenblatt, D. J., Krystal, J. H., Nardi, A. E., Rickels, K., et al. (2018) · Psychotherapy and Psychosomatics

Pharmaceutical Practices and Patient OutcomesAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 35

The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and Discontinuation

Koff, J. M., Pritchard, G. A., Greenblatt, D. J., & Miller, L. G. (2008) · Pharmacology

Neuroscience and Neuropharmacology ResearchEpilepsy research and treatment

Cited by 33

Nighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia

Bliwise, D. L., Seidel, W. F., Greenblatt, D. J., & Dement, W. C. (1984) · American Journal of Psychiatry

Sleep and related disordersSleep and Work-Related Fatigue

Cited by 33

Pharmocokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test

Greenblatt, D. J., Gan, L., Harmatz, J. S., & Shader, R. I. (2005) · British Journal of Clinical Pharmacology

Anesthesia and Sedative AgentsPharmacogenetics and Drug Metabolism

Cited by 33

Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications

Greenblatt, D. J., & Zammit, G. K. (2012) · Expert Opinion on Drug Metabolism & Toxicology

Sleep and related disordersPharmacogenetics and Drug Metabolism

Cited by 28

Alterations in pharmacodynamics of anxiolytics in abstinent alcoholic men: subjective responses, abuse liability, and electroencephalographic effects of alprazolam, diazepam, and buspirone

Ciraulo, D. A., Barnhill, J. G., Ciraulo, A. M., Sarid‐Segal, O., Knapp, C., Greenblatt, D. J., & Shader, R. I. (1997) · The Journal of Clinical Pharmacology

Substance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on Behavior

Cited by 28